Integral Health Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Integral Health Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50,000	Closed	-$5.27M	–	110
2026 Q1	$5.27M	Buy	+50,000	New	+$4.43M	0.25%	75
2023 Q3	–	Sell	-75,000	Closed	-$2.07M	–	88
2023 Q2	$2.07M	Buy	+75,000	New	+$1.88M	0.26%	69
2021 Q4	–	Sell	-35,000	Closed	-$620K	–	81
2021 Q3	$620K	Buy	+35,000	New	+$1.49M	0.18%	68

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Integral Health Asset Management's PTGX Position: Q2 2026 in Review

Integral Health Asset Management sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 50,000 shares — an estimated $5.27M sold.

Integral Health Asset Management first reported a position in PTGX in Q3 2021 and held it in 3 quarters. The position peaked at $5.27M in Q1 2026. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Integral Health Asset Management reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
Integral Health Asset Management sold 50,000 Protagonist Therapeutics shares in Q2 2026, an estimated $5.27M.
Integral Health Asset Management first reported a position in Protagonist Therapeutics in Q3 2021 and held it in 3 quarters.
Integral Health Asset Management's Protagonist Therapeutics position peaked at $5.27M in Q1 2026.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.